Sensorion wins French ANSM clearance to launch Phase I/II SENS-601 gene therapy trial for GJB2 hearing loss

• Sensorion won French ANSM clearance to start HearConnex, a Phase I/II trial of SENS-601 gene therapy for GJB2-related hearing loss.
• First patient dosing targeted for early 2027 in France; clinical data expected through 2027.
• Health Canada review of a June 2026 clinical trial application remains on track; U.S. IND filing targeted by end-2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sensorion SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260902715548) on September 03, 2026, and is solely responsible for the information contained therein.